The increase in price target from $39 to $60 by a reputable analyst suggests a positive reassessment of Apellis Pharmaceuticals' potential value or growth prospects. While the rating remains Neutral, the significant raise in target price could lead to increased investor confidence and a potential short-term uplift in the stock price.